12% CONVERTIBLE PROMISSORY NOTE DUE AUGUST 8, 2019Rasna Therapeutics Inc. • August 9th, 2018 • Pharmaceutical preparations • New York
THIS CONVERTIBLE PROMISSORY NOTE is one of a series of duly authorized and validly issued Notes of Rasna Therapeutics, Inc., a Nevada corporation, (the “Borrower”), having its principal place of business at 420 Lexington Avenue, Suite 2525, New York, New York 10170, due August 8, 2019 (this note, the “Note” and, collectively with the other notes of such series, the “Notes”).
